Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
SOPHARMA AD (the “Company”) hereby informs that from 21 August 2014 up to and including 27 August 2014 the Company bought 1 280 own shares representing 0.00097% of the share capital of the Company, to the total value of 5 400.92 BGN on the Bulgarian Stock Exchange, the average price per share was 4.219 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 067 155, representing 3.84% of the share capital of the Company.
SOPHARMA AD (the “Company”) notifies that for October 2013 the Company recorded a decrease of sales revenues of 3% compared to the same period of 2012, including 5% decrease of domestic sales and 3% decrease of export sales.
During the past ten months Sopharma AD recorded a decrease of sales revenues of 1%, including 5% increase of domestic sales and 3% decrease of export sales compared to the same period of 2012.
SOPHARMA AD (the “Company”) hereby informs that from 31 October 2013 up to and including 6 November 2013 the Company bought 17 612 own shares representing 0.013% of the share capital of the Company, to the total value of 57 936.2 BGN on the Bulgarian Stock Exchange. The average price per share was 3.29 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 368 415, representing 4.07% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 7 November 2013 up to and including 13 November 2013 the Company bought 23,436 own shares representing 0.018% of the share capital of the Company, to the total value of 79 264.03 BGN on the Bulgarian Stock Exchange. The average price per share was 3.38 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 391 581, representing 4.08% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 14 November 2013 up to and including 20 November 2013 the Company bought 7 570 own shares representing 0.006% of the share capital of the Company, to the total value of 26 414.24 BGN on the Bulgarian Stock Exchange. The average price per share was 3.49 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 399 421, representing 4.09% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 21 November 2013 up to and including 27 November 2013 the Company bought 10 019 own shares representing 0.0076% of the share capital of the Company, to the total value of 35 268.79 BGN on the Bulgarian Stock Exchange. The average price per share was 3.52 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 409 440, representing 4.10% of the share capital of the Company.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 09 August 2012 up to and including 15 August 2012 the Company bought 2200 own shares representing 0.0017% of the share capital of the Company, at a total value of BGN 5320.76 on the Bulgarian Stock Exchange. The average price per share was BGN 2.42.
The shares have been bought on the basis of the general meeting resolution of 23.06.2010.
SOPHARMA AD (the “Company”) hereby informs that from 28 August 2014 up to and including 3 September 2014 the Company bought 4900 own shares representing 0.0037% of the share capital of the Company, to the total value of 20 687.8 BGN on the Bulgarian Stock Exchange, the average price per share was 4.222 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 072 055, representing 3.84% of the share capital of the Company.
SOPHARMA AD hereby informs that the Company will commence the paying of dividends for 2013 on 11 September 2014 in accordance with a List of Entitled Persons as at 4 July 2014, prepared by the Central Depository.
Sopharma AD (the “Company”) notifies that for August 2014 the Company recorded a decrease of sales revenues of 11% compared to the same period of 2013, including 9% increase of domestic sales and 19% decrease of export sales.
During the past eight months Sopharma AD recorded a decrease of sales revenues of 6%, including 3% increase of domestic sales and 9% decrease of export sales compared to 2013.
